Nick Norwitz MD PhD Profile picture
Nov 6, 2022 11 tweets 8 min read Read on X
🚨 NEW! Lean Mass Hyper-Responder Editorial🚨

👉 10 MD & PhD authors from 4 countries🌍coming together for 1st of it's kind Consensus Statement on #LMHR

👉 Published in official Journal of the National Lipid Association @LipidJournal

A thread 🧵👇
authors.elsevier.com/a/1g22A6tb2E2O… Image
2/ A bit of background to catch some of you up

Over the past 6 years a population of people has emerged who demonstrate ⬆️ LDL on a #ketogenic diet in the context of ⬇️TG +⬆️HDL

Phenotype was first observed by @realDaveFeldman and (historically) named Lean Mass Hyper-Responders Image
3/ 1 year ago, we started researching #LMHR more formally, and in this year, we've published 4 prior papers

Cohort Study
pubmed.ncbi.nlm.nih.gov/35106434/
Case Report
pubmed.ncbi.nlm.nih.gov/35498420/
Cholesterol drop protocol
pubmed.ncbi.nlm.nih.gov/35938774/
Lipid Energy Model
pubmed.ncbi.nlm.nih.gov/35629964/
4/ With this editorial we take the NEXT STEP in providing an expert consensus of 10 MD + PhD authors on topic of #LDL in #LMHR on a #ketodiet, including incredibly highly respected members of the Lipidology community
authors.elsevier.com/a/1g22A6tb2E2O…
5/ Major take-aways:

A prudent PATIENT-CENTERED clinical approach is required for managing #LMHR patients

The #LMHR phenomenon deserves FURTHER RESEARCH, both on mechanism and risk, and has potential to teach us much about human lipid metabolism and ASCVD
6/ Some of my favorite linesare as follows 👇

"LMHR provide[s] a unique opportunity to understand LDL-c dynamics beyond what has previously been possible”

“where there are competing medical conditions, weighing of treatment options should be an individual matter” ImageImageImageImage
7/ It was a true pleasure to put together this editorial with my coauthors @MichaelMindrum, Dr. Giral, Professor Anatol Kontush, @AdrianSotoMota, @DrRagnar (Tommy Wood), @DominicDAgosti2, Dr. Manubolu, @BudoffMd, and Dr. Ronald Krauss. I cannot speak highly enough of this team Image
8/ I also want to give a HUGE shout out to the LMHR Facebook group + @realDaveFeldman who collectively helped to fund the open access fee despite being blinded to article itself and purely out of a devotion to open-access science and in moving this particular discussion forward
9/ Also, check out Dave's 2:29 min video here. Always high production quality!

10/ I will have more to say on this editorial in the coming days and weeks, but for now I encourage you to read it for yourself (it's concise!) and help to amplify this important discussion! 🙏🙏🙏
authors.elsevier.com/a/1g22A6tb2E2O…

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Nick Norwitz MD PhD

Nick Norwitz MD PhD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @nicknorwitz

Dec 15
Have High Lp(a)? You Need to See Today's Video covering a new 2025 study on Lp(a) and waist-to-hip ratio

1/5) Here's a quick breakdown...

The goal of this new study was to determine whether a measure of adiposity—waist-to-hip ratio—modifies the relationship between Lp(a) and cardiovascular disease risk.Image
2/5) To explore this, researchers analyzed data from 4,652 participants in the Multi-Ethnic Study of Atherosclerosis (MESA), following them over a median of 17.4 years.

The study stratified individuals based on Lp(a) levels defined as >50 mg/dL and investigated how this risk interacted with waist-to-hip ratio as a marker of central adiposity and visceral fat

*Lp(a) (nmol/L) = Lp(a) (mg/dL) x 2.15Image
3/5) And—remarkably—in individuals with a ↓ waist-to-hip ratio, Lp(a) levels were not significantly associated with increased cardiovascular risk…

Full video: Image
Read 5 tweets
Dec 13
New Study: Person Study Finds Statin Use Associated Decline in Muscle Mass

1/6) A colleague of mine—a medical doctor—texted me recently: “I’m stopping my statin.”

The new paper referenced concludes: “Continuous statin use is associated with a decline in muscle function and mass over time (25% decline in grip strength and 73% decline in appendicular lean mass compared to never-­ users).”

Let’s discuss. (links in 5/6 and 6/6)Image
2/6) We’ll break this up by discussing the cross-sectional (single time point) and longitudinal (over time) results.

Cross-sectional analysis: In the fully adjusted model, adjusting for age, sex, education, smoking, BMI, activity score, diet quality score, high blood pressure, diabetes, and so on, statin use was associated with lower grip strength and lower appendicular lean mass.
3/6) Longitudinal Analysis: Statin Use Associated with Steeper Muscle Decline

Echoing the prior analysis, continuous statin use was significantly associated with accelerated declining grip strength and lean mass.

*Nuance note: For those with keen eyes, we discuss the y-intercept in the full letter

TL;DR: Statins use is linked to fasting muscular decline.Image
Read 6 tweets
Dec 11
Sardines Accidentally Supercharged my Metabolism?(link in 8/8)

1/8) Now, I want to follow-up on one of the strangest findings from the Sardine Diet Experiment...

I became cold-resistant.

Taking off my shirt on an icy Boston winter day felt almost like a cool, soothing summer breeze.

It felt weird. It was unexpected. But it also makes sense... Let's discuss...Image
2/8) As a quick recap, I recently did a self-experiment that can be summarized in just two words: Sardine Diet. After a couple weeks on this extremely high omega-3 diet, I became conspicuously cold-resistant.

This was weird.

And I wanted to understand what might be happening. So, I dug into the literature.Image
3/8) Here's what could be happening...

Metabolically active brown fat can convert omega-3 fatty acids into a hormone called 12-HEPE.

12-HEPE stimulates thermogenesis in brown fat and ramps up glucose uptake into muscle as well.

This ultimately promotes heat production, cold adaptation, and energy expenditure.

Now, let’s get into some data…Image
Read 8 tweets
Dec 9
The Best form of Omega-3 Matters (🔗 in 8/8)

(1/8) Alzheimer’s disease is personal for me. In my early 20s, I discovered I carry the ApoE4/4 genotype—placing me at the highest genetic risk. I was terrified. But over time, that fear shifted to a realization:
👉A genetic predisposition is a vulnerability, not a destiny.
👉 Our choices shape our health trajectory more than our genes ever could.

Today, I want to share a piece of that puzzle: The Omega-3 Paradox.

👉The Signal: Data clearly shows eating fatty fish lowers Alzheimer’s rates and boosts cognitive longevity.
👉The Failure: Yet, large clinical trials using Omega-3 supplements often fail to protect the brain.
👉The Question: Why?

One answer lies in a specific delivery mechanism most people—and many researchers—overlook.

Here is the science of getting Omega-3s into the brain. 🧵👇Image
(2/8) So, why do supplements often miss the mark? The answer is likely the form in which the Omega-3s are packaged.

When you eat seafood, you ingest Omega-3s in diverse forms, including phospholipids. However, most supplements on the shelf provide them in other forms, like triglycerides.

The Form Matters…Image
(3/8) The Form of Omega-3 Matters.

Think of it like this: Consuming DHA as a free fatty acid triglyceride is like mailing a letter with no address. It enters your system, but it doesn't know where to go. It rarely reaches the brain.

But if you have phospholipid-bound DHA? That’s like sending a letter via express courier, straight to the correct neuron. More specifically, the “express courier” form is called Lyso-DHA.

This specific form has special access to the brain through a transporter called MFSD2A.

Without the phospholipid "address," the DHA gets lost in transit.Image
Read 8 tweets
Dec 7
How Metabolic Disease Feeds Emotional Eating 🧠🍩
(link at the end)

1/8) A brand new study (Dec 10, 2025) reveals how poor metabolic health can drive emotional eating.

Why this is important: There’s a known link between metabolic disease (obesity, diabetes, etc.) and mental health conditions (eating disorders, anxiety, depression).

But the causal relationships remain murky.

In uncovering the “how” we lay the groundwork for innovative solutions.

cc @Metabolic_Mind @janellison @TuitNutrition @ChrisPalmerMD @MitoPsychoBio @WilliamFurness @drjenunwinImage
2/8) The researchers behind the experiments took interest in ImP, which is known to be elevated in patients with metabolic conditions like diabetes (below)—and is linked to cardiometabolic disease.

*ImP levels are elevated in humans with type 2 diabetes (red) vs healthy controls (blue).Image
3/8) Given the link between metabolic diseases and mental health, the researchers set out to test a new hypothesis:

If you increase ImP, does that change the brain and behavior?

To do this, they fitted mice with a tiny pump that continuously delivered ImP at levels designed to mimic what’s seen in people with diabetes.

Afterward, they looked for neural changes and found a large shift in gene-expression programs within neurons tied to the stress response in the hypothalamus.

Those molecular changes lined up with behavior.
Read 8 tweets
Dec 6
When The “Cholesterol Drop” Misses the Mark
(Links in 6/7 and 7/7)

1/7) Can we assume that how much LDL drops tells us how much cardiovascular risk is reduced?

A new meta-analysis in the European Heart Journal says, “No.”

In fact, it suggests the link between LDL-C reduction and actual cardiovascular outcomes is incredibly weak.

So, have we built a multi-billion-dollar industry on the assumption that hot chocolate equals real illness?

Let’s unpack that…

cc @realDaveFeldman @AdrianSotoMota @ApoDudz @DrEricRodgers @LDLSkeptic @AKoutnik @janellison @bschermdImage
2/7) This was an umbrella review of meta-analyses of randomized controlled trials.

In total, the review included 20 RCTs comprising 194,686 participants, with a median follow-up of 4.85 years.

So, what did they find?

In this study, the r² for LDL-C on major adverse cardiovascular events ranged from 0 to 0.1.

In other words, this calls into serious question whether LDL-C can be used as a surrogate for clinical outcomes in statin trials.Image
3/7) To better define r2 (pronounced “R-squared”)… it’s a number that tells you how well one thing predicts another. It ranges from 0 to 1 (or 0% to 100%):

r² = 1 means perfect prediction — knowing the first number tells you exactly what the second will be.

r² = 0 means no prediction — the first number tells you nothing about the second.

r² <0.1 ... is terrible!

It’s like trying to predict who will win the marathon based on who tied their shoes the tightest.Image
Read 7 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(